MedPath

Hemin

Generic Name
Hemin
Brand Names
Panhematin
Drug Type
Biotech
CAS Number
16009-13-5
Unique Ingredient Identifier
743LRP9S7N
Background

Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.

Indication

Used in the management of porphyria attacks, particularly in acute intermittent porphyria.

Associated Conditions
Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria
Clinical Trials
Related News

Acute Porphyria Biomarkers for Disease Activity

Active, not recruiting
Conditions
Acute Intermittent Porphyria
Variegate Porphyria
Hereditary Coproporphyria
Interventions
First Posted Date
2016-10-17
Last Posted Date
2025-04-18
Lead Sponsor
The University of Texas Medical Branch, Galveston
Target Recruit Count
50
Registration Number
NCT02935400
Locations
🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria

Phase 2
Completed
Conditions
Acute Porphyrias
Interventions
Other: Glucose
First Posted Date
2014-07-02
Last Posted Date
2025-04-11
Lead Sponsor
The University of Texas Medical Branch, Galveston
Target Recruit Count
20
Registration Number
NCT02180412
Locations
🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis

Phase 2
Completed
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Drug: placebo
First Posted Date
2013-05-17
Last Posted Date
2021-07-07
Lead Sponsor
Erasme University Hospital
Target Recruit Count
284
Registration Number
NCT01855841
Locations
🇧🇪

Hôpital Ambroise Paré, Mons, Belgium

🇧🇪

Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium

🇧🇪

CHU Brugmann, Brussels, Belgium

and more 3 locations

Hemin in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: placebo infusion
First Posted Date
2009-04-17
Last Posted Date
2009-04-17
Lead Sponsor
Mayo Clinic
Target Recruit Count
10
Registration Number
NCT00882804
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

Phase 2
Terminated
Conditions
Myelodysplastic Syndrome
Interventions
First Posted Date
2007-04-30
Last Posted Date
2014-10-24
Lead Sponsor
Rush University Medical Center
Target Recruit Count
6
Registration Number
NCT00467610
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy